Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide Tryngolza in the third quarter, building up toward a regulatory submission in hypertriglyceridemia by year-end.